I am planning on restoring macrophages' phagocytic ability in cancer-related settings, but I only want to target tumor-associated macrophages and not tissue resident M0 macrophage as well. As a result, I was wondering if there is some antibody or inhibitor that selectively targets SIRPa in M2 macrophages. Another question is, if I endowed a nanoparticle with both an M2 targeting peptide and a SIRPa antibody, would it target M2 macrophages over other macrophage phenotypes and immune cells such as dendritic cells.